Interaction analysis of high-risk pathological features on adjuvant chemotherapy survival benefit in stage II colon cancer patients: a multi-center, retrospective study

被引:0
|
作者
Li, Kexuan [1 ]
Zhao, Fuqiang [2 ]
Guo, Yuchen [3 ]
Wu, Qingbin [4 ]
Luo, Shuangling [5 ,6 ,7 ]
Zhang, Junling [8 ]
Li, Heli [9 ]
Hu, Shidong [10 ]
Wu, Bin [1 ]
Lin, Guole [1 ]
Qiu, Huizhong [1 ]
Niu, Beizhan [1 ]
Sun, Xiyu [1 ]
Xu, Lai [1 ]
Lu, Junyang [1 ]
Du, Xiaohui [10 ]
Wang, Zheng [9 ]
Wang, Xin [8 ]
Kang, Liang [5 ,6 ,7 ]
Wang, Ziqiang [4 ]
Wang, Quan [3 ]
Liu, Qian [2 ]
Xiao, Yi [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Gen Surg, Div Colorectal Surg, 1 Shuai Fu Yuan Rd, Beijing 100730, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp,Dept Diagnost Radiol, 17 Panjiayuan Nanli, Beijing 100021, Peoples R China
[3] First Hosp Jilin Univ, Gen Surg Ctr, Dept Gastrointestinal Surg, 1 Xin Min Ave, Changchun 130021, Peoples R China
[4] Sichuan Univ, West China Hosp, Colorectal Canc Ctr, Dept Gen Surg, 37 Guo Xue Xiang, Chengdu 610041, Peoples R China
[5] Sun Yat sen Univ, Affiliated Hosp 6, Dept Gen Surg Colorectal Surg, 26 Yuan Cun Er Heng Rd, Guangzhou 510655, Peoples R China
[6] Sun Yat sen Univ, Affiliated Hosp 6, Guangdong Prov Key Lab Colorectal & Pelv Floor Dis, 26 Yuan Cun Er Heng Rd, Guangzhou 510655, Peoples R China
[7] Sun Yat sen Univ, Affiliated Hosp 6, Biomed Innovat Ctr, 26 Yuan Cun Er Heng Rd, Guangzhou 510655, Peoples R China
[8] Peking Univ First Hosp, Dept Gastrointestinal Surg, 8 Xi Shi Ku St, Beijing 100034, Peoples R China
[9] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Gastrointestinal Surg, 1277 Jiefang Ave, Wuhan 430022, Peoples R China
[10] Chinese Peoples Liberat Army PLA Gen Hosp, Med Ctr 1, Dept Gen Surg, 28 Fu Xing Rd, Beijing 100853, Peoples R China
基金
中国国家自然科学基金;
关键词
Colon cancer; High-risk pathological features; Adjuvant chemotherapy; PERINEURAL INVASION; PREDICTIVE FACTOR; PROGNOSTIC-FACTOR; OXALIPLATIN; FLUOROURACIL; LEUCOVORIN; OUTCOMES; THERAPY; TRIAL;
D O I
10.1186/s12885-023-11196-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background We aimed to analyze the benefit of adjuvant chemotherapy in high-risk stage II colon cancer patients and the impact of high-risk factors on the prognostic effect of adjuvant chemotherapy. Methods This study is a multi-center, retrospective study, A total of 931 patients with stage II colon cancer who underwent curative surgery in 8 tertiary hospitals in China between 2016 and 2017 were enrolled in the study. Cox proportional hazard model was used to assess the risk factors of disease-free survival (DFS) and overall survival (OS) and to test the multiplicative interaction of pathological factors and adjuvant chemotherapy (ACT). The additive interaction was presented using the relative excess risk due to interaction (RERI). The Subpopulation Treatment Effect Pattern Plot (STEPP) was utilized to assess the interaction of continuous variables on the ACT effect. Results A total of 931 stage II colon cancer patients were enrolled in this study, the median age was 63 years old (interquartile range: 54-72 years) and 565 (60.7%) patients were male. Younger patients (median age, 58 years vs 65 years; P < 0.001) and patients with the following high-risk features, such as T4 tumors (30.8% vs 7.8%; P < 0.001), grade 3 lesions (36.0% vs 22.7%; P < 0.001), lymphovascular invasion (22.1% vs 6.8%; P < 0.001) and perineural invasion (19.4% vs 13.6%; P = 0.031) were more likely to receive ACT. Patients with perineural invasion showed a worse OS and marginally worse DFS (hazardous ratio [HR] 2.166, 95% confidence interval [CI] 1.282-3.660, P = 0.004; HR 1.583, 95% CI 0.985-2.545, P = 0.058, respectively). Computing the interaction on a multiplicative and additive scale revealed that there was a significant interaction between PNI and ACT in terms of DFS (HR for multiplicative interaction 0.196, p = 0.038; RERI, -1.996; 95%CI, -3.600 to -0.392) and OS (HR for multiplicative interaction 0.112, p = 0.042; RERI, -2.842; 95%CI, -4.959 to -0.725). Conclusions Perineural invasion had prognostic value, and it could also influence the effect of ACT after curative surgery. However, other high-risk features showed no implication of efficacy for ACT in our study.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Impact of adjuvant chemotherapy on long-term overall survival in patients with high-risk stage II colon cancer: a nationwide cohort study
    Rosberg, Victoria
    Jessen, Mikkel
    Qvortrup, Camilla
    Smith, Henry George
    Krarup, Peter-Martin
    ACTA ONCOLOGICA, 2023, 62 (09) : 1076 - 1082
  • [22] Identification of patients with high-risk stage II colon cancer for adjuvant therapy
    Quah, Hak-Mien
    Chou, Joanne F.
    Gonen, Mithat
    Shia, Jinru
    Schrag, Deborah
    Landmann, Ron G.
    Guillem, Jose G.
    Paty, Philip B.
    Temple, Larissa K.
    Wong, W. Douglas
    Weiser, Martin R.
    DISEASES OF THE COLON & RECTUM, 2008, 51 (05) : 503 - 507
  • [23] Impact of adjuvant chemotherapy on survival for patients with Stage II colon cancer
    Stitzenberg, K. B.
    Stewart, A.
    Palis, B.
    Bilimoria, K.
    Minsky, B.
    Sigurdson, E.
    ANNALS OF SURGICAL ONCOLOGY, 2008, 15 : 89 - 89
  • [24] Role of adjuvant chemotherapy in patients with pathological stage I NSCLC with high-risk features.
    Arjyal, Lubina
    Uprety, Dipesh
    Frankki, Susan M.
    Borgert, Andrew J.
    Marinier, David E.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] Individualized Lifetime Survival Benefit of Adjuvant Chemotherapy in the Treatment of Stage II Colon Cancer
    Millen, Janelle-Cheri
    Chang, Shu-Ching
    Grunkemeier, Gary
    Nelson, Daniel
    Fischer, Trevan
    Morton, Donald L.
    Goldfarb, Melanie
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 1) : S210 - S210
  • [26] Adjuvant Chemotherapy Use and Outcomes of Patients With High-Risk Versus Low-Risk Stage II Colon Cancer
    Kumar, Aalok
    Kennecke, Hagen F.
    Renouf, Daniel J.
    Lim, Howard J.
    Gill, Sharlene
    Woods, Ryan
    Speers, Caroline
    Cheung, Winson Y.
    CANCER, 2015, 121 (04) : 527 - 534
  • [27] Adjuvant Chemotherapy Benefit in Elderly Stage II/III Colon Cancer Patients
    Chen, Xin
    Tu, Junhao
    Xu, Xiaolan
    Gu, Wen
    Qin, Lei
    Qian, Haixin
    Jia, Zhenyu
    Ma, Chuntao
    Xu, Yinkai
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [28] Effectiveness of oral fluoropyrimidine monotherapy as adjuvant chemotherapy for high-risk stage II colon cancer
    Cho, Jung Rae
    Lee, Keun-Wook
    Oh, Heung-Kwon
    Kim, Jin Won
    Kim, Ji-Won
    Kim, Duck-Woo
    Kim, Jee Hyun
    Kang, Sung-Bum
    ANNALS OF SURGICAL TREATMENT AND RESEARCH, 2022, 102 (05) : 271 - 280
  • [29] Elevated Carcinoembryonic Antigen Warrants Adjuvant Chemotherapy in High-risk Stage II Colon Cancer
    Wilson, Tanner B.
    Narayanan, Sowmya
    Khan, Sidrah
    Althans, Alison R.
    Paniccia, Alessandro
    Zureikat, Amer H.
    Kaltenmeier, Christof
    Lee, Kenneth K.
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (SUPPL 2) : 380 - 380
  • [30] Microsatellite Status Predicts Effectiveness of Adjuvant Chemotherapy in High-Risk Stage II Colon Cancer
    Krishnamurty, Devi Mukkai
    Park, Yu-Soon A.
    Tashjian, Nara
    Aurit, Sarah J.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2019, 229 (04) : S65 - S66